Article - European Medical Journal

Continue

Articles

Oncology
12 Nov 2015

Current and Future Developments in the Treatment of CD30+ Lymphomas

CD30 is a cell membrane protein expressed on the surface of a range of lymphomas, which has important diagnostic, pathogenic, and prognostic roles.
Diabetes
3 Nov 2015

Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits

Type 2 diabetes mellitus (T2D) is one of the most serious global health problems. This is partly a result of its drastic increase in East Asia…
Diabetes
3 Nov 2015

Benefits of Bariatric Surgery and Perioperative Surgical Safety

Obesity is a worldwide problem with numerous associated health problems. The number of patients eligible for surgery outnumber surgical capacity…
Diabetes
3 Nov 2015

Moderate Hypoxia Exposure: A Novel Strategy to Improve Glucose Metabolism in Humans?

The obesity epidemic calls for novel strategies to prevent and treat obesity and its comorbidities. Several studies have indicated that…
Diabetes
3 Nov 2015

The Concept of Early Vascular Ageing – An Update in 2015

Arterial ageing is a process that can be quantified, at least to some degree, by measurement of pulse wave velocity along the aorta…
Diabetes
3 Nov 2015

REST/NRSF Target Genes in Neuronal and Beta Cells: Pathophysiological and Therapeutic Perspectives for Diabetes and Neurodegenerative Disorders

Pancreatic beta and neuronal cells share numerous similarities, including a key transcriptional mechanism of the differentiation programme.
Diabetes
3 Nov 2015

Transforming Growth Factor Beta-Based Therapies, a Potential Modulator of the Immune Response in Type 1 Diabetes?

Immunobiological interventions are proving to be an exciting new area for mobilising the immune response towards certain tumours.
Cardiology
20 Oct 2015

International, Large-Scale, Real-World Clinical Data Confirm the Safety Profile of Rivaroxaban

Rivaroxaban is a direct factor Xa inhibitor and a non-vitamin K antagonist (VKA) novel oral anticoagulant (NOAC) approved for a number of indications.